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ABSTRACT
Objectives: It is unclear whether the high prevalence of
herpes simplex virus type 2 (HSV-2) found in much of
Africa predates the HIV epidemic or is, to some extent, a
consequence of it. HSV-2 prevalence trends in a rural
African community were assessed over a period in which
HIV prevalence rose sharply, and antenatal clinic (ANC)
surveillance was explored as a method of estimating
community HSV-2 prevalence.
Methods: HSV-2 seroprevalence was determined among
community controls seen for case–control studies of
mycobacterial disease in Karonga district, Malawi, in
1988–90, 1998–2001 and 2002–5, and in women
attending ANC as part of surveillance for HIV in 1999–
2000. Over this period HIV prevalence rose from 4%
to 12%.
Results: HSV-2 prevalence in all periods increased
sharply with age and was higher in women than in men.
After excluding migrants, there was no evidence of
change in HSV-2 prevalence in the different periods.
Women in the ANC group had lower HSV-2 prevalence
than those in the community, but the ANC prevalence
was a good approximation to the combined male and
female prevalence for the same age group.
Conclusions: This study suggests that HSV-2 was
already widespread before the HIV epidemic and has not
been greatly influenced by it. It also demonstrates that
ANC surveillance may be useful for estimating community
HSV-2 prevalence.
Herpes simplex virus type 2 (HSV-2) may both
increase susceptibility to HIV infection and
enhance its transmission. HSV-2 infection is
associated with a threefold increased risk of HIV
acquisition in both men and women.1 2 HSV-2
prevalence is high in many populations, especially
in Africa;3 it is possible that HSV-2 is a major
determinant of the differential distribution of HIV
between populations.4 5 It is, however, currently
unclear whether the high rates of HSV-2 now seen
in association with HIV are a cause or, to some
extent, a consequence of the high prevalence of
HIV. HIV co-infection has been associated with
increased severity and duration of HSV-2 ulcera-
tion and increased HSV-2 shedding,6 so increased
transmission of HSV-2 is likely. There is no
information available on long-term trends of
HSV-2 in Africa.
In Karonga district, Malawi, we assessed HSV-2
prevalence over the period in which HIV preva-
lence rose from 4% to 12%.7 We also assessed
socioeconomic determinants of HSV-2, associa-
tions with HIV in different time periods and the
possible use of antenatal clinic (ANC) surveillance
for measuring HSV-2 prevalence.
METHODS
Karonga district is a rural area in northern Malawi
with a population of approximately 250 000. Total
population surveys were conducted in Karonga
district in 1981–4 and 1986–9 for studies of
mycobacterial disease. A case–control study of
tuberculosis and leprosy was started in 1988; controls
were selected from people seen in the second survey,
age, sex and area matched to the cases, with up to
four controls per case8 9 Individuals who had moved
away and any new immigrants were not included.
A new case–control study of tuberculosis was
started in 1998. Controls were stratum-matched to
the cases by age, sex and area, each year. They were
selected using field-based random sampling.10
Random starting points in the field were chosen in
proportion to population density in the second
survey; a direction was chosen using a spinning top
and the first person within a pre-specified age and sex
band was selected. The controls at each period were
therefore a random sample of the general population,
but with an age, sex and area distribution similar to
that of tuberculosis and leprosy cases. From 1998 new
immigrants were included. Only the controls from
these case–control studies were used in these analyses.
Controls were interviewed and blood was taken
for HIV testing, after counselling and if consent
was given. For controls seen in 1988–90 informa-
tion on socioeconomic variables was only available
from the 1981–4 survey and was not used for this
analysis. Socioeconomic data were collected during
the 1998–2005 household visits. ANC surveillance
for HIV was started in 1999 in four clinics using
unlinked anonymous testing.11
In 1988–90 initial HIV testing used an ELISA
(Vironostika; Organon Teknika, Cambridge, UK)
and particle agglutination test (Edgeware modifica-
tion of the Serodia). Positives were confirmed using a
further ELISA (Wellcozyme Wellcome Diagnostics,
Dartford, UK or Enzygnost, Behring, Marburg,
Germany) and particle agglutination assay (Serodia,
Fujirebio Inc, Tokyo, Japan). From 1998, the first two
tests were conducted as before, and samples giving
discrepant results were repeated in duplicate using
the same two tests. Western blot and repeat testing
was used if there were continued discrepancies. From
1998 to 2001 individuals who did not want to give
serum samples could give urine samples and from
2002 they could give saliva samples. Urine testing
used GACPAT;12 results that were not clearly
negative on the first test were repeated and any
doubtful results were excluded. Saliva testing initially
used GACELISA for a few early samples and Orasure
Advance (Orasure Technologies Inc, Bethlehem,
Pennsylvania, USA) rapid tests in the laboratory for
the majority.
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Stored sera from the controls and the ANC surveillance were
tested for HSV-2 using a type-2-specific enzyme immunoassay
(Kalon Biological Ltd, Surrey, UK), which has the highest
sensitivity and specificity of commercially available assays when
used on African samples.13 Sera from people aged 15–44 years
were tested in 1988–90 and 2002–5, and those from all adults
aged 15 years and over from 1998 to 2001. Permission for the
original studies, and testing of the stored sera for HSV-2, was
received from the Health Sciences Research Committee,
Malawi, and from the ethics committee of the London School
of Hygiene and Tropical Medicine.
Analyses compared the prevalence of HSV-2 at different
periods, allowing for age, sex and area. Prevalence was estimated
using direct standardisation, taking the population of the
district in 1998 as the standard, using 5-year age groups and
six areas.11 Because of the different methods of control selection,
prevalence was also re-calculated for the later periods excluding
those who had moved in the past 5 years, to make them
comparable with the controls from 1988–90. Sociodemographic
determinants of HSV-2 were assessed using logistic regression,
using age, sex and area as a priori confounders. The association
between HSV-2 and HIV seropositivity was explored.
HSV-2 prevalence in women attending ANC in 1999–2000
was compared with that in women in the community in 1998–
2001. Factors associated with differences in prevalence were
explored in a logistic regression analysis by assessing which
factors confounded the association between ANC use and HSV-
2 status.14 All analyses used STATA version 9.
RESULTS
HSV-2 results were available from 677 controls from 1988 to
1990, 719 from 1998 to 2001, 383 from 2002 to 2005 and from
981 women attending ANC.
In the early period, 8.6% of controls refused venepuncture.
HSV-2 testing was limited to adults aged 15–44 years. Of 811
specimens, a consecutive series of 116 were lost from storage. Of
the remaining 695 sera, 14 were missing and four gave equivocal
results for HSV-2.
In 1998–2001, of 995 individuals seen as controls, 728 (73%)
gave blood for HIV testing (62% of the remainder gave urine
specimens and the rest refused testing). Of the 728 specimens,
two gave equivocal results for HSV-2 and seven were missing.
Among those without HSV-2 results available in this period,
women, the youngest and oldest age groups, those living in the
urban and periurban area and those without schooling were
overrepresented. The other sociodemographic factors and HIV
prevalence were similar in those with and without HSV-2
results.
In 2002–5 saliva testing was used rather than urine for those
not wanting to give blood for HIV. Of 573 controls aged 15–
44 years, 424 (74%) gave blood for testing and 69% of the rest
gave saliva. Of the 424, HSV-2 results were equivocal for three
and missing for 38. In this period, women, younger and older
age groups, those living in the southern and central parts of the
district and those who were HIV positive were overrepresented
among those without HSV-2 results.
HSV-2 prevalence
HSV-2 prevalence by age, sex and time period, including directly
standardised estimates, is shown in table 1. HSV-2 prevalence
rose with age in all periods and was higher in women than in
men, reaching 70% by age 40 years. The difference in HSV-2
prevalence between periods was most marked in the younger
age groups but was similar for men and women. Restricting to
those aged 15–44 years, HSV-2 prevalence was higher in 1998–
2001 than in 1988–90: odds ratio (OR) 1.47, 95% CI 1.14 to 1.90
Table 2 Associations between socioeconomic factors and HSV-2, 1998–2005, in adults aged 15–44 years
Men Women Crude OR
OR adjusted for age,
sex, area, and period
OR (95% CI)
OR adjusted for age,
sex, area, period and
moved in past 5 years
or possession score
OR (95% CI)
HSV-2+/N % HSV-2+/N % OR (95% CI)
Moved in past 5 years p = 0.2 p,0.001 p,0.001
No move 136/271 50.2 180/307 58.6 1 1 1
From elsewhere in district 12/62 19.4 96/146 65.8 0.90 (0.6 to 1.23) 1.40 (0.96 to 2.05) 1.50 (1.01 to 2.23)
From outside district 25/45 55.6 40/58 69.0 1.4 (0.92 to 2.18) 2.60 (1.57 to 4.28) 2.64 (1.59 to 4.40)
Occupation p = 0.4 p = 0.6
Farmers 96/222 43.2 219/343 63.9 1 1
Non-farmers 71/150 47.3 93/162 57.4 0.88 (0.67 to 1.16) 1.09 (0.78 to 1.52)
Schooling p = 0.002 p = 0.4
,6 Years primary 28/56 50.0 132/197 67.0 1 1
6–8 Years primary 86/184 46.7 139/236 58.9 0.67 (0.49 to 0.92) 0.79 (0.55 to 1.12)
Secondary/tertiary 58/137 42.3 44/76 57.9 0.53 (0.37 to 0.77) 0.87 (0.56 to 1.34)
Housing score p = 0.9 p = 0.7
1 (worst) 48/117 41.0 107/166 64.5 1 1
2 32/64 50.0 42/77 54.6 0.91 (0.61 to 1.37) 0.92 (0.59 to 1.44)
3 60/120 50.0 96/163 58.9 1.01 (0.73 to 1.41) 1.11 (0.76 to 1.62)
4 (best) 29/71 40.9 65/96 67.7 1.06 (0.72 to 1.56) 1.22 (0.77 to 1.93)
Possession score p = 0.004 p = 0.02 p = 0.03
1 (worst) 20/50 40.0 41/65 63.1 1 1 1
2 39/95 41.1 81/136 59.6 0.96 (0.61 to 1.50) 1.0 (0.61 to 1.64) 1.02 (0.62 to 1.67)
3 81/171 47.4 115/208 55.3 0.95 (0.62 to 1.44) 0.92 (0.58 to 1.45) 0.98 (0.61 to 1.56)
4 (best) 31/57 54.4 73/96 76.0 1.88 (1.14 to 3.10) 1.79 (1.03 to 3.10) 1.86 (1.06 to 3.25)
Housing score depends on housing materials.
Possession score depends on the number of household items (bicycle, motor vehicle, canoe/oxcart, bankbook, clock, radio, cattle) owned, weighted by relative value.
HSV-2, herpes simplex virus type 2; OR, odds ratio.
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after adjusting for age, sex and area, but similar in the latest
period (adjusted OR 1.15, 95% CI 0.86 to 1.52). After excluding
those who had moved within the past 5 years from the two
later periods, to make the control selection more equivalent to
that in the earliest period, the age–sex–area-adjusted OR was
1.24 (0.93 to 1.66) in 1998–2001 and 1.11 (0.80 to 1.53) in 2002–
5. Among those aged less than 25 years, excluding those who
had moved in the past 5 years, HSV-2 prevalence was 24% (52/
216) in 1988–90 and 22% (15/68) in 1998–2005 (combined
due to small numbers); age–sex–area-adjusted OR 0.73 (0.35
to 1.53).
Associations with socioeconomic status, 1998–2005
Information on socioeconomic factors was only available for the
years 1998–2005 (table 2). After adjusting for age, sex, area and
time period, the HSV-2 prevalence was similar in farmers and
non-farmers, and varied little by schooling level or housing type.
It was higher in those who had moved in the past 5 years and
those who had most household possessions. The associations
with movement and possessions became slightly stronger after
additionally adjusting for each other.
Associations with HIV status in adults aged 15–44 years
In 1988–90 1.4% (3/222) HSV-2-negative men and 6.4% (7/110)
HSV-2-positive men were HIV positive. For women the results
were 2.0% (3/151) and 5.7% (11/192). The OR for the
association of HSV-2 and HIV, adjusted for age and area, was
4.0 (0.97 to 17) for men and 3.1 (0.78 to 12.2) for women. In
1998–2005, among men, 4.4% (9/204) of HSV-2 negatives and
27% (47/173) of HSV-2 positives were HIV positive, OR,
adjusted for age, area and time period, 7.8 (3.5 to 7.4). Among
women equivalent figures were 4.7% (9/192), 26.0% (82/316)
and 9.0 (4.1–19.7).
HSV-2 prevalence in ANC (1999–2000) and community (1998–
2001)
HSV-2 prevalence was lower in women in the ANC group than
in the community in the same period (table 1). Among women
aged 15–44 years, those in the ANC group were younger than
those in the community (mean 24.5 years compared with 30.9),
came from slightly different areas, were more likely to be
currently married (93% compared with 79%), were less likely to
have previous children, were more likely to have moved recently
within the district, but were less likely to have moved from
outside and had a higher level of schooling. Similar proportions
came from farming households. Comparing the crude preva-
lence of HSV-2 between ANC women and those in the
community, the OR was 0.47 (0.36 to 0.61). This was largely
explained by the age difference: age-adjusted OR 0.72 (0.54 to
0.97). Additionally adjusting for area made no difference.
Additionally adjusting for marital status increased the OR to
0.79 (0.58 to 1.07); adding movement in the past 5 years
increased the OR to 0.83 (0.61 to 1.13) and adding previous
children increased it further to 0.85 (0.62 to 1.7). Adjusting for
schooling and occupation made no difference to the results.
(Housing and possession information was not available in the
ANC.) The age and area-standardised prevalence in the ANC
group (47.2%, table 1) was similar to that for men and women
combined (46.4%).
DISCUSSION
HSV-2 prevalence was already high in the late 1980s, when HIV
prevalence was low, so the high prevalence is not a result of the
HIV epidemic. An apparent increase in HSV-2 prevalence in the
late 1990s is largely explicable by the inclusion of individuals
who had moved recently. In all time periods the community
samples were randomly selected, and after adjusting for age, sex
and area, should have been representative of the whole district.
In the early period refusal rates were low and the lost sera will
not have biased the results, but individuals who had moved
since the survey were not included. In the later surveys
movement was associated with higher HSV-2 prevalence.
After excluding those who had moved from the later surveys,
the difference between the periods was much reduced and not
significant. A higher HSV-2 prevalence in those who are more
mobile is not unexpected, as this is often found for HIV,
reflecting higher sexual risk and movement related to marriage.15
In the later surveys refusal rates were higher and there were
some differences between those who refused and those who did
not. Differences in age, sex and area were accounted for in the
analysis, but the underrepresentation of those with no school-
ing among those tested may have led to a slight overestimate of
HSV-2 prevalence. On the other hand, HIV prevalence was
higher in those who gave saliva samples; there may have been
some false positives, or high-risk individuals may have refused
blood tests, which would underestimate HSV-2 prevalence in
the most recent period.
The data therefore provide little evidence of a real increase in
HSV-2 prevalence over time. We have previously shown that
HIV rose earliest and highest in the urban area,16 but this is not
reflected in the HSV-2 prevalence distribution, consistent with
HIV not having a major influence on HSV-2 prevalence. In rural
Uganda and Tanzania, HSV-2 prevalence was also already high
in the general population by 1989/1992,3 and high HSV-2
prevalence has been reported in West Africa in the 1980s,
although the age and population groups are not clear.17 This
suggests that HSV-2 was already widespread in Africa before
the HIV epidemic, and that HIV infection is not an important
determinant of the HSV-2 prevalence in the population. This
conclusion is also supported by mathematical modelling of the
Ugandan HIV epidemic, in which stable HSV-2 prevalence was
attributed to the small increase due to enhanced transmission
by HIV being balanced by the effects of HIV-related mortality,18
and by modelling of the interaction of HIV and HSV-2 in
Kisumu, Kenya.19
ANC data are used in HIV surveillance, and the biases are
well known.20 Here we explored the potential of ANC data for
HSV-2 prevalence estimation. As for HIV, the ANC data
underestimated prevalence. This was seen in all age groups,
whereas an overestimation in the youngest age group would be
expected, reflecting differences in sexual activity; however, the
number of young women among the community controls was
small. For HIV, one bias is the direct biological effect on fertility,
whereas for HSV-2 the bias appears to reflect sociodemographic
differences in fertility and hence ANC use. As has previously
been shown for HIV, the lower estimate of prevalence for
women from the ANC group compared with the population,
together with the higher prevalence in women than in men in
the population, result in the prevalence of HSV-2 in the ANC
group approximating to that in the population for men and
women combined.
HSV-2 infection is a major determinant of HIV infection risk
at the individual and perhaps at the population level.5 We
provide further evidence that HSV-2 was widespread in Africa
before HIV and is not simply a result of the HIV epidemic, and
suggest that HSV-2 prevalence can be estimated using ANC
surveillance.
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Key messages
c Although HIV infection increases HSV-2 transmission, we
show that HSV-2 prevalence was already high in the early
years of the HIV epidemic and was not greatly influenced by
increasing HIV prevalence.
c ANC surveillance can be used to estimate population level
HSV-2 prevalence.
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